Jazz Pharmaceuticals has acquired Cavion as part of its expansion plans in Philadelphia. The deal will mean an upfront payment of $52.5 million plus additional payments worth up to $260 million upon completion of specific regulatory and commercial milestones that were not disclosed.
Va. biotech Cavion acquired by Jazz Pharmaceuticals
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.